Lisata Therapeutics Stock Performance
| LSTA Stock | USD 4.57 0.02 0.44% |
Lisata Therapeutics holds a performance score of 12 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of 1.09, which conveys a somewhat significant risk relative to the market. Lisata Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Lisata Therapeutics is expected to follow. Use Lisata Therapeutics expected short fall, and the relationship between the value at risk and daily balance of power , to analyze future returns on Lisata Therapeutics.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Lisata Therapeutics are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unfluctuating basic indicators, Lisata Therapeutics sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (0.22) | Five Day Return 0.88 | Year To Date Return 132.65 | Ten Year Return (94.57) | All Time Return (100.00) |
Last Split Factor 1:15 | Last Split Date 2022-09-15 |
1 | 3T Biosciences Announces Appointments of Behzad Kharabi, M.D., as Chief Medical Officer, and Parker Institute for Cancer Immunotherapy CEO Karen Knudsen, MBA, P... | 01/06/2026 |
2 | Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635 | 01/12/2026 |
3 | Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for 4.00 Per Share in an All-Cash Tender Offer | 01/21/2026 |
4 | Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia | 01/26/2026 |
5 | Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide | 01/27/2026 |
6 | Genflow Biosciences PLC Announces Holding in Company | 01/30/2026 |
7 | A Look At Becton Dickinson Valuation After Mixed Recent Share Price Performance | 02/04/2026 |
8 | Disposition of 26964 shares by Mazzo David J of Lisata Therapeutics at 2.93 subject to Rule 16b-3 | 02/06/2026 |
9 | BD Reports First Quarter Fiscal 2026 Financial Results | 02/09/2026 |
10 | Becton Dickinson Resets Core Focus With Spin Off And 2b Buyback | 02/13/2026 |
| Begin Period Cash Flow | 22.6 M | |
| Total Cashflows From Investing Activities | 13.2 M | |
| Free Cash Flow | -19.4 M |
Lisata Therapeutics Relative Risk vs. Return Landscape
If you would invest 199.00 in Lisata Therapeutics on November 20, 2025 and sell it today you would earn a total of 258.00 from holding Lisata Therapeutics or generate 129.65% return on investment over 90 days. Lisata Therapeutics is currently generating 1.8631% in daily expected returns and assumes 11.6135% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Lisata, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Lisata Therapeutics Target Price Odds to finish over Current Price
The tendency of Lisata Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 4.57 | 90 days | 4.57 | nearly 4.46 |
Based on a normal probability distribution, the odds of Lisata Therapeutics to move above the current price in 90 days from now is nearly 4.46 (This Lisata Therapeutics probability density function shows the probability of Lisata Stock to fall within a particular range of prices over 90 days) .
Lisata Therapeutics Price Density |
| Price |
Predictive Modules for Lisata Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Lisata Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Lisata Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Lisata Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Lisata Therapeutics is not an exception. The market had few large corrections towards the Lisata Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Lisata Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Lisata Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 1.53 | |
β | Beta against Dow Jones | 1.09 | |
σ | Overall volatility | 1.10 | |
Ir | Information ratio | 0.14 |
Lisata Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Lisata Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Lisata Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Lisata Therapeutics is way too risky over 90 days horizon | |
| Lisata Therapeutics appears to be risky and price may revert if volatility continues | |
| Lisata Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 1000 K. Net Loss for the year was (19.98 M) with profit before overhead, payroll, taxes, and interest of 1.07 M. | |
| Lisata Therapeutics currently holds about 72.99 M in cash with (19.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 18.07, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Lisata Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 20.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: Becton Dickinson Resets Core Focus With Spin Off And 2b Buyback |
Lisata Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Lisata Stock often depends not only on the future outlook of the current and potential Lisata Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Lisata Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 8.3 M | |
| Cash And Short Term Investments | 31.2 M |
Lisata Therapeutics Fundamentals Growth
Lisata Stock prices reflect investors' perceptions of the future prospects and financial health of Lisata Therapeutics, and Lisata Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Lisata Stock performance.
| Return On Equity | -0.72 | ||||
| Return On Asset | -0.42 | ||||
| Operating Margin | (18.77) % | ||||
| Current Valuation | 18.39 M | ||||
| Shares Outstanding | 8.82 M | ||||
| Price To Book | 2.32 X | ||||
| Price To Sales | 37.59 X | ||||
| Revenue | 1000 K | ||||
| Gross Profit | 1.07 M | ||||
| EBITDA | (22.23 M) | ||||
| Net Income | (19.98 M) | ||||
| Cash And Equivalents | 72.99 M | ||||
| Cash Per Share | 18.07 X | ||||
| Total Debt | 137 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 22.33 X | ||||
| Book Value Per Share | 1.98 X | ||||
| Cash Flow From Operations | (19.36 M) | ||||
| Earnings Per Share | (2.13) X | ||||
| Market Capitalization | 40.22 M | ||||
| Total Asset | 35 M | ||||
| Retained Earnings | (548.07 M) | ||||
| Working Capital | 28.96 M | ||||
About Lisata Therapeutics Performance
By analyzing Lisata Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Lisata Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Lisata Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Lisata Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 4.4 K | 4.6 K | |
| Return On Tangible Assets | (0.52) | (0.54) | |
| Return On Capital Employed | (0.69) | (0.72) | |
| Return On Assets | (0.51) | (0.54) | |
| Return On Equity | (0.78) | (0.82) |
Things to note about Lisata Therapeutics performance evaluation
Checking the ongoing alerts about Lisata Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Lisata Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Lisata Therapeutics is way too risky over 90 days horizon | |
| Lisata Therapeutics appears to be risky and price may revert if volatility continues | |
| Lisata Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 1000 K. Net Loss for the year was (19.98 M) with profit before overhead, payroll, taxes, and interest of 1.07 M. | |
| Lisata Therapeutics currently holds about 72.99 M in cash with (19.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 18.07, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Lisata Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 20.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: Becton Dickinson Resets Core Focus With Spin Off And 2b Buyback |
- Analyzing Lisata Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Lisata Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Lisata Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Lisata Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Lisata Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Lisata Therapeutics' stock. These opinions can provide insight into Lisata Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Lisata Stock analysis
When running Lisata Therapeutics' price analysis, check to measure Lisata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lisata Therapeutics is operating at the current time. Most of Lisata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Lisata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lisata Therapeutics' price. Additionally, you may evaluate how the addition of Lisata Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |